Recent LSBC Activities
- June 2, 2020: LSBC's President & CEO, Wendy Hurlburt, hosted a virtual meeting with STEMCELL's, Senior Vice President, Business Operations, Dr. David Llewellyn. They discussed STEMCELL's undertaking re. the COVID 19 pandemic and the expansion of their business globally within the next few years. LINK to Event (available until June 10, 2020)
- June 3, 2020: Wendy hosted the VANTEC Health & Life Sciences event to discuss Investing in Life Sciences and HealthTech (Link to be provided on LSBC website next week)
- Government Relations: LifeSciences BC one on one calls with Hon. Michelle Mungall, Ministry of Jobs, Economic Development and Competitiveness and Deputy Minster, Fazil Mihlar to discuss the role of the life science sector as B.C. restarts it's economy and the overall impact of its ecosystem.
Note:When available, going forward, videos of LSBC events will be posted to coincide with ongoing events
|
Recruiting speakers for a community project called Convergence
Convergence is an organization founded in 2020 by UBC students looking to provide high school students personal insight on future career opportunities. Our goal is to educate high school students and aid them in deciding on a career choice. We aim to achieve this by giving students the chance to listen to presentations from members of the working community and university students with a strong passion towards a discipline.
The deadline to complete the form is July 15, 2020 @ 11:59 PM.
|
Bold Therapeutics Executes Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea
VANCOUVER, British Columbia, May 27, 2020 / PRNewswire/ - Bold Therapeutics, a clinical-stage biopharmaceutical company, announced it has executed an option agreement with an undisclosed publicly traded company for exclusive rights to BOLD-100 in South Korea.
READ MORE
|
Neoleukin Therapeutics Announces Appointment of Erin Lavelle to Board of Directors
SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) - Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Erin Lavelle to the company's Board of Directors.
READ MORE
|
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting
SAN DIEGO, June 1, 2020 /PRNewswire/ -
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that two posters updating results from the company's two Phase 2 clinical trials of VAL-083 will be presented at the 2020 American Association for Cancer Research Virtual Annual Meeting II to be held June 22-24, 2020.
READ MORE
|
Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
BURNABY, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 pm Eastern time.
READ MORE
|
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
VICTORIA, British Columbia-(BUSINESS WIRE)- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 p.m. EDT.
READ MORE
|
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
BERKELEY, Calif., VANCOUVER, British Columbia and SEATTLE, Wash., June 02, 2020 (GLOBE NEWSWIRE) - Aduro Biotech, Inc. ("
Aduro") (NASDAQ: ADRO) and Chinook Therapeutics, Inc. ("Chinook"), a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the companies have entered into a definitive merger agreement....
READ MORE
|
Aurinia Announces Results of Annual General Meeting
VICTORIA, British Columbia-(BUSINESS WIRE)-Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) ("Aurinia" or the "Company") is pleased to announce that the nine incumbent directors of the Company were elected at the Company's annual general meeting held on June 2, 2020 (the "Meeting").
READ MORE
|
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in
Glioblastoma Multiforme
SAN DIEGO, June 4, 2020 /PRNewswire/ -
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today .....
READ MORE
|
New Company to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain
Montreal, Canada - June 4, 2020: adMare BioInnovations, Canada's Global Life Sciences Venture, along with partners McGill University and AmorChem II Fund l.p., a leading early-stage venture capital fund, is advancing made-in-Canada research that aims to provide new opiate-sparing pain-relieving drugs.
READ MORE
|
Merck to Announce Multiple
Scientific
Efforts to
Combat COVID-19
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three signicant scientic initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today's announcements are....READ MORE
|
PFIZER ESTABLISHES NEW PROGRAM TO SUPPORT CONTINUED BIOTECHNOLOGY INNOVATION
Pfizer Breakthrough Growth Initiative will invest up to $500 million across a portfolio of clinical-stage biotechnology companies
Tuesday, June 02, 2020 -
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the establishment of the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help provide funding and access to Pfizer's scientific expertise to ensure continuity of the biotechnology companies' most promising clinical development programs.
READ MORE
|
EMPLOYMENT OPPORTUNITIES and PROGRAMS
|
What could your company do with $20,000 in wage subsidies?
Wage Subsidies for Hiring Young Talent
The Career Starter Program facilitates the transition for youth facing challenges entering the labour market and increases their knowledge of the sector's needs through recent and practical work experience. The program provides 50% of the youth's salary to a maximum of $20,000 in wage subsidies for a 3 to 9-months placement.
Are you eligible?
As a resource to the bio-economy, BioTalent Canada is continuing its operations virtually including accepting wage subsidy applications, and processing claims as quickly as possible. Employers, uncertain if your job qualifies or would like to be pre-qualified before you hire?
Contact:
|
approximately 60,000 visitors a month?
~
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on Biotalent's
The Petri Dish?
After your first five reposts, you will also receive 25% off all job postings on
The Petri Dish!
Want more info? Please contact Sue Callaghan at
|
DUE TO THE COVID 19 VIRUS, LIFESCIENCES BC STAFF ARE WORKING FROM HOME. WE WILL RETURN TO NORMAL WORKING CONDITIONS ONCE GOVERNMENT HAS SAID IT IS SAFE TO DUE SO.
UNTIL THEN, WE ARE ALL REACHABLE BY EMAIL LISTED
HERE
.
|
|
|
|